schliessen

Filtern

 

Bibliotheken

Altering APP Proteolysis: Increasing sAPPalpha Production by Targeting Dimerization of the APP Ectodomain (APP-Interacting Compounds Target APP Dimerization)

One of the events associated with Alzheimer's disease is the dysregulation of α- versus β-cleavage of the amyloid precursor protein (APP). The product of α-cleavage (sAPPα) has neuroprotective properties, while Aβ1-42 peptide, a product of β-cleavage, is neurotoxic. Dimerization of APP has been show... Full description

Journal Title: PLoS ONE 2012, Vol.7(6), p.e40027
Main Author: Libeu, Clare A. Peters
Other Authors: Descamps, Olivier , Zhang, Qiang , John, Varghese , Bredesen, Dale E
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: E-ISSN: 1932-6203 ; DOI: 10.1371/journal.pone.0040027
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: plos10.1371/journal.pone.0040027
title: Altering APP Proteolysis: Increasing sAPPalpha Production by Targeting Dimerization of the APP Ectodomain (APP-Interacting Compounds Target APP Dimerization)
format: Article
creator:
  • Libeu, Clare A. Peters
  • Descamps, Olivier
  • Zhang, Qiang
  • John, Varghese
  • Bredesen, Dale E
subjects:
  • Research Article
  • Biology
  • Medicine
  • Molecular Biology
  • Biotechnology
  • Pharmacology
  • Neurological Disorders
  • Biochemistry
ispartof: PLoS ONE, 2012, Vol.7(6), p.e40027
description: One of the events associated with Alzheimer's disease is the dysregulation of α- versus β-cleavage of the amyloid precursor protein (APP). The product of α-cleavage (sAPPα) has neuroprotective properties, while Aβ1-42 peptide, a product of β-cleavage, is neurotoxic. Dimerization of APP has been shown to influence the relative rate of α- and β- cleavage of APP. Thus finding compounds that interfere with dimerization of the APP ectodomain and increase the α-cleavage of APP could lead to the development of new therapies for Alzheimer's disease. Examining the intrinsic fluorescence of a fragment of the ectodomain of APP, which dimerizes through the E2 and Aβ-cognate domains, revealed significant changes in the fluorescence of the fragment upon binding of Aβ oligomers—which bind to dimers of the ectodomain— and Aβ fragments—which destabilize dimers of the ectodomain. This technique was extended to show that RERMS-containing peptides (APP 695 328–332), disulfiram, and sulfiram also inhibit dimerization of the ectodomain fragment. This activity was confirmed with small angle x-ray scattering. Analysis of the activity of disulfiram and sulfiram in an AlphaLISA assay indicated that both compounds significantly enhance the production of sAPPα by 7W-CHO and B103 neuroblastoma cells. These observations demonstrate that there is a class of compounds that modulates the conformation of the APP ectodomain and influences the ratio of α- to β-cleavage of APP. These compounds provide a rationale for the development of a new class of therapeutics for Alzheimer's disease.
language: eng
source:
identifier: E-ISSN: 1932-6203 ; DOI: 10.1371/journal.pone.0040027
fulltext: fulltext
issn:
  • 1932-6203
  • 19326203
url: Link


@attributes
ID102679686
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid10.1371/journal.pone.0040027
sourceidplos
recordidTN_plos10.1371/journal.pone.0040027
sourcesystemOther
pqid1325036141
galeid477004452
display
typearticle
titleAltering APP Proteolysis: Increasing sAPPalpha Production by Targeting Dimerization of the APP Ectodomain (APP-Interacting Compounds Target APP Dimerization)
creatorLibeu, Clare A. Peters ; Descamps, Olivier ; Zhang, Qiang ; John, Varghese ; Bredesen, Dale E
contributorIijima, Koichi M. (Editor)
ispartofPLoS ONE, 2012, Vol.7(6), p.e40027
identifierE-ISSN: 1932-6203 ; DOI: 10.1371/journal.pone.0040027
subjectResearch Article ; Biology ; Medicine ; Molecular Biology ; Biotechnology ; Pharmacology ; Neurological Disorders ; Biochemistry
descriptionOne of the events associated with Alzheimer's disease is the dysregulation of α- versus β-cleavage of the amyloid precursor protein (APP). The product of α-cleavage (sAPPα) has neuroprotective properties, while Aβ1-42 peptide, a product of β-cleavage, is neurotoxic. Dimerization of APP has been shown to influence the relative rate of α- and β- cleavage of APP. Thus finding compounds that interfere with dimerization of the APP ectodomain and increase the α-cleavage of APP could lead to the development of new therapies for Alzheimer's disease. Examining the intrinsic fluorescence of a fragment of the ectodomain of APP, which dimerizes through the E2 and Aβ-cognate domains, revealed significant changes in the fluorescence of the fragment upon binding of Aβ oligomers—which bind to dimers of the ectodomain— and Aβ fragments—which destabilize dimers of the ectodomain. This technique was extended to show that RERMS-containing peptides (APP 695 328–332), disulfiram, and sulfiram also inhibit dimerization of the ectodomain fragment. This activity was confirmed with small angle x-ray scattering. Analysis of the activity of disulfiram and sulfiram in an AlphaLISA assay indicated that both compounds significantly enhance the production of sAPPα by 7W-CHO and B103 neuroblastoma cells. These observations demonstrate that there is a class of compounds that modulates the conformation of the APP ectodomain and influences the ratio of α- to β-cleavage of APP. These compounds provide a rationale for the development of a new class of therapeutics for Alzheimer's disease.
languageeng
source
version9
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
search
creatorcontrib
0Libeu, Clare A. Peters
1Descamps, Olivier
2Zhang, Qiang
3John, Varghese
4Bredesen, Dale E
5Iijima, Koichi M. (Editor)
titleAltering APP Proteolysis: Increasing sAPPalpha Production by Targeting Dimerization of the APP Ectodomain (APP-Interacting Compounds Target APP Dimerization)
descriptionOne of the events associated with Alzheimer's disease is the dysregulation of α- versus β-cleavage of the amyloid precursor protein (APP). The product of α-cleavage (sAPPα) has neuroprotective properties, while Aβ1-42 peptide, a product of β-cleavage, is neurotoxic. Dimerization of APP has been shown to influence the relative rate of α- and β- cleavage of APP. Thus finding compounds that interfere with dimerization of the APP ectodomain and increase the α-cleavage of APP could lead to the development of new therapies for Alzheimer's disease. Examining the intrinsic fluorescence of a fragment of the ectodomain of APP, which dimerizes through the E2 and Aβ-cognate domains, revealed significant changes in the fluorescence of the fragment upon binding of Aβ oligomers—which bind to dimers of the ectodomain— and Aβ fragments—which destabilize dimers of the ectodomain. This technique was extended to show that RERMS-containing peptides (APP 695 328–332), disulfiram, and sulfiram also inhibit dimerization of the ectodomain fragment. This activity was confirmed with small angle x-ray scattering. Analysis of the activity of disulfiram and sulfiram in an AlphaLISA assay indicated that both compounds significantly enhance the production of sAPPα by 7W-CHO and B103 neuroblastoma cells. These observations demonstrate that there is a class of compounds that modulates the conformation of the APP ectodomain and influences the ratio of α- to β-cleavage of APP. These compounds provide a rationale for the development of a new class of therapeutics for Alzheimer's disease.
subject
0Research Article
1Biology
2Medicine
3Molecular Biology
4Biotechnology
5Pharmacology
6Neurological Disorders
7Biochemistry
general
010.1371/journal.pone.0040027
1English
sourceidplos
recordidplos10.1371/journal.pone.0040027
issn
01932-6203
119326203
rsrctypearticle
creationdate2012
recordtypearticle
addtitle
0PLoS ONE
1APP-Interacting Compounds Target APP Dimerization
searchscopeplos
scopeplos
lsr30VSR-Enriched:[galeid, pqid]
sort
titleAltering APP Proteolysis: Increasing sAPPalpha Production by Targeting Dimerization of the APP Ectodomain (APP-Interacting Compounds Target APP Dimerization)
authorLibeu, Clare A. Peters ; Descamps, Olivier ; Zhang, Qiang ; John, Varghese ; Bredesen, Dale E
creationdate20120629
facets
frbrgroupid8189281964923729862
frbrtype5
languageeng
creationdate2012
topic
0Research Article
1Biology
2Medicine
3Molecular Biology
4Biotechnology
5Pharmacology
6Neurological Disorders
7Biochemistry
collectionPLoS
prefilterarticles
rsrctypearticles
creatorcontrib
0Libeu, Clare A. Peters
1Descamps, Olivier
2Zhang, Qiang
3John, Varghese
4Bredesen, Dale E
5Iijima, Koichi M.
jtitlePLoS ONE
toplevelpeer_reviewed
frbr
t2
k12012
k219326203
k310.1371/journal.pone.0040027
k47
k56
k640027
k7plos one
k8altering app proteolysis increasing sappalpha production by targeting dimerization of the app ectodomain
k9alteringappproteolysomain
k12alteringappproteolysisinc
k15clareapeterslibeu
k16libeuclareapeters
delivery
delcategoryRemote Search Resource
fulltextfulltext
ranking
booster11
booster21
pcg_typepublisher
addata
aulast
0Libeu
1Descamps
2Zhang
3John
4Bredesen
5Iijima
aufirst
0Clare A. Peters
1Olivier
2Qiang
3Varghese
4Dale E.
5Koichi M.
au
0Libeu, Clare A. Peters
1Descamps, Olivier
2Zhang, Qiang
3John, Varghese
4Bredesen, Dale E
addauIijima, Koichi M.
atitleAltering APP Proteolysis: Increasing sAPPalpha Production by Targeting Dimerization of the APP Ectodomain (APP-Interacting Compounds Target APP Dimerization)
jtitlePLoS ONE
risdate20120629
volume7
issue6
spagee40027
pagese40027
eissn1932-6203
genrearticle
ristypeJOUR
abstractOne of the events associated with Alzheimer's disease is the dysregulation of α- versus β-cleavage of the amyloid precursor protein (APP). The product of α-cleavage (sAPPα) has neuroprotective properties, while Aβ1-42 peptide, a product of β-cleavage, is neurotoxic. Dimerization of APP has been shown to influence the relative rate of α- and β- cleavage of APP. Thus finding compounds that interfere with dimerization of the APP ectodomain and increase the α-cleavage of APP could lead to the development of new therapies for Alzheimer's disease. Examining the intrinsic fluorescence of a fragment of the ectodomain of APP, which dimerizes through the E2 and Aβ-cognate domains, revealed significant changes in the fluorescence of the fragment upon binding of Aβ oligomers—which bind to dimers of the ectodomain— and Aβ fragments—which destabilize dimers of the ectodomain. This technique was extended to show that RERMS-containing peptides (APP 695 328–332), disulfiram, and sulfiram also inhibit dimerization of the ectodomain fragment. This activity was confirmed with small angle x-ray scattering. Analysis of the activity of disulfiram and sulfiram in an AlphaLISA assay indicated that both compounds significantly enhance the production of sAPPα by 7W-CHO and B103 neuroblastoma cells. These observations demonstrate that there is a class of compounds that modulates the conformation of the APP ectodomain and influences the ratio of α- to β-cleavage of APP. These compounds provide a rationale for the development of a new class of therapeutics for Alzheimer's disease.
copSan Francisco, USA
pubPublic Library of Science
doi10.1371/journal.pone.0040027
oafree_for_read
date2012-06-29